| Identification | Back Directory | [Name]
[2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol | [CAS]
85081-18-1 | [Synonyms]
NBI-98782
(+)-α-DHTBZ
(+)-α-Dihydrotetrabenazine
Tetrabenazine metabolite A
Tetrabenazine metabolite B
Tetrabenazine Related Impurity 27
Tetrabenazine Related Impurity 27 (2R, 3R, 11bR)
(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol
(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-ol
(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol
2H-Benzo[a]quinolizin-2-ol, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-, (2R,3R,11bR)-
[2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol | [Molecular Formula]
C19H29NO3 | [MDL Number]
MFCD08061467 | [MOL File]
85081-18-1.mol | [Molecular Weight]
319.44 |
| Chemical Properties | Back Directory | [Melting point ]
106-108 °C(Solv: hexane (110-54-3)) | [Boiling point ]
457.8±45.0 °C(Predicted) | [density ]
1.13 | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 33.33 mg/mL (104.34 mM; Need ultrasonic) | [form ]
Powder | [pka]
14.75±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
(+)-α-Dihydrotetrabenazine is a potent inhibitor of vascular monoamine transporter 2 (VMAT2) and an agent of significant interest for therapeutic and molecular imaging applications. | [Definition]
ChEBI: (2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol is a member of isoquinolines. | [in vivo]
NBI-98782 (10 mg/kg, p.o., daily for 7 days) decreases basal and APDs-induced monoamine efflux in both mPFC and dSTR in male C57BL/6J mice[1].
| Animal Model: | Male C57BL/6J mice[1] | | Dosage: | 10 mg/kg | | Administration: | p.o., daily for 7 days | | Result: | Decreased the efflux of DA, 5-HT and NE in mPFC, dSTR, HIP and NAC.
Increased the efflux of DOPAC, HVA, and 5-HIAA in mPFC, dSTR, HIP and NAC.
Decreased in cortical DA and DOPAC as well as striatal DA, 5-HT and NE efflux combinated with haloperidol (HY-14538, 0.5 mg/kg, i.p.).
Decreased cortical Glu and striatal ACh, DA and GABA efflux combinated with Clozapine (HY-14539, 10 mg/kg, i.p.).
Reduced PCP-induced increase in LMA between various time points.
Suppressed clozapine-, olanzapine- and risperidone-induced DA efflux in both mPFC and dSTR, and ACh efflux in mPFC.
|
| [storage]
Store at -20°C |
|
|